Welcome to BCIQ: BioCentury Online Intelligence.
Free access to this and other abridged company profiles is provided to all subscribers to SciBX: Science-Business eXchange.

Please explore the profile and if you wish to find out more about BCIQ - please Click Here

Aeterna Zentaris Inc.

Print preview

(TSX:AEZ; NASDAQ:AEZS)
formerly known as Aeterna Laboratories Inc.

General Information

Location	Quebec City, Quebec
Region	Quebec
Country	Canada
Business Category	Endocrine, Infectious, Cancer
Year Founded	1991
Website	www.aeternazentaris.com
Development Status	Market (drug) (10/26/2005)

Archive Items are loading

Financial Information

Financing Summary

Total Money Raised	Number of Completed Financings	Last Financing Date	Last Financing Type	Number of All Financings
$128,044,554	8	06/24/2009	Direct public offering (other)	8

Financing Details (8 records)

Company Name	Financing Status	Date Completed	Financing Type	Amount Raised	Share Price	Post-Money Valuation
Aeterna Zentaris Inc.	Completed	06/24/2009	Direct public offering (other)	$10,000,000	$1.88	$109,992,444
Aeterna Laboratories Inc.	Completed	07/24/2003	Follow-on	$25,262,000	C$7.90	$253,739,240

Financial Performance Summary

	1Q08	2Q08	3Q08	4Q08	1Q09
As Of Date	03/31/2008	06/30/2008	09/30/2008	12/31/2008	03/31/2009
Profit and loss
Sales	$7,942,000	$8,250,000	$8,630,000	$4,640,000	$4,971,000
Revenues	$9,748,000	$10,457,000	$11,029,000	$7,244,000	$6,111,000
SG&A	$4,404,000	$6,606,000	$3,277,000	$3,038,000	$3,554,000
R&D	$13,689,000	$17,345,000	$13,880,000	$12,328,000	$11,437,000
Operating Income	($14,158,000)	($19,525,000)	($12,386,000)	($16,315,000)	($13,442,000)
Net Income	($10,866,000)	($20,579,000)	($13,879,000)	($14,493,000)	($12,388,000)
EPS	-$0.20	$0.39	-$0.26	-$0.27	-$0.23
Diluted EPS
Shares Outstanding	53,187,000	53,187,000	53,187,000	53,678,000	53,187,000
Balance Sheet
Cash	$38,714,000	$24,827,000	$10,957,000	$49,719,000	$62,471,000
Valuations
Market Cap	$54,782,610	$55,846,350	$31,380,330	$26,302,220	$46,804,560
Tech Value	$16,068,610	$31,019,350	$20,423,330	($23,416,780)	($15,666,440)
R&D/Sales
R&D/Revenue	1.40	1.66	1.26	1.70	1.87
SG&A/Sales	0.55	0.80	0.38	0.65	0.71
SG&A/Revenue	0.45	0.63	0.30	0.42	0.58
Currency Rate
Rate	1.0000	1.0000	1.0000	1.0000	1.0000

Stocks Annual Chart

Pipeline Information

Pipeline Summary

Disease Category	Research	Phase I	Phase I/II	Phase II	Phase II/III	Phase III	Registration	Approved	Marketed
Cancer	6	2	-	10	-	-	-	-	-
Endocrine	-	1	-	-	-	-	-	-	1
Genitourinary	3	-	-	1	-	2	-	-	-
Infectious	-	-	-	-	-	-	-	-	1
Total	9	3	-	11	-	2	-	-	2

Pipeline Details - Originated and out-licensed products (27 records)

Product Names	Disease Category	Standard Indication	Partners	Milestones	Latest Stage of Development
AEZS-108 (Compound #), AN-152 (Former compound #), ZEN-008 (Former compound #)	Cancer	Endometrial cancer			Phase II
AEZS-108 (Compound #), AN-152 (Former compound #), ZEN-008 (Former compound #)	Cancer	Ovarian cancer			Phase II

Pipeline Details - In-licensed products

ACCESS TO BIOCENTURY ONLINE INTELLIGENCE (BCIQ) AND THE BIOCENTURY ARCHIVES IS LIMITED ONLY TO AUTHORIZED SUBSCRIBERS WHO HAVE READ AND AGREED TO THE BIOCENTURY USER AGREEMENT, WHICH SOLELY GOVERNS THE CONDITIONS FOR USE OF ANY OF THESE SERVICES AND THE INFORMATION CONTAINED THEREIN. All contents Copyright © 1994-2009 BioCentury Publications, Inc. ALL RIGHTS RESERVED. These Services and the Content contained therein are protected under U.S. and foreign copyright and intellectual property laws, and may not be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BioCentury Publications, Inc., P.O. Box 1246 San Carlos, CA 94070.